Company intelligence / Profile preview

New England Cell Therapeutics

New Haven, Connecticut, United Statesbioct.org ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

New England Cell Therapeutics is a development-stage biotech company focused on delivering mesenchymal stem cell therapies to treat a range of injuries and illnesses. Its lead program, STR04, is in Phase 2 clinical trials for Amyotrophic Lateral Sclerosis (ALS), with the first trial set to start recruiting in April 2025. The company’s research also spans other nervous system and metabolic diseases. No published clinical results are available as of April 2025.

Therapeutic areas: EndocrinologyNeurology
Modalities: Mesenchymal stem cell therapyStem cell replacements
Industry: Biotech

Drug pipeline

1 asset

STR-04

Unknown

Beyond the preview

Go deeper on New England Cell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New England Cell Therapeutics.

Explore the full profile